Investors

/Investors
Investors 2018-12-09T14:40:37+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.92
-0.08 (-2.00%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :22,319
Date :12-14-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

November 13th, 2018|Comments Off on Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more [...]

Oramed to Present at the Tides Europe 2018 Conference

November 5th, 2018|Comments Off on Oramed to Present at the Tides Europe 2018 Conference

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]

Oramed to Present at Cardiometabolic Health Congress

October 23rd, 2018|Comments Off on Oramed to Present at Cardiometabolic Health Congress

NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two [...]

Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

October 4th, 2018|Comments Off on Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first [...]